Pepgen INC

PepGen Inc. provided an update on its investigational therapy PGN-EDODM1 for Myotonic Dystrophy Type 1, highlighting promising safety and efficacy data from its FREEDOM studies.

PepGen posted topline results from the lowest-dose 5 mg/kg Phase 2 FREEDOM2-DM1 cohort showing clean safety, modest mean splicing vs placebo but stronger effect excluding one outlier, vHOT improvement trends, and maintained guidance for 10 mg/kg data in 2H 2026 with cash runway into 2H 2027.

PepGen Inc. updated its corporate presentation, highlighting positive single-dose splicing correction data for PGN-EDODM1 in Myotonic Dystrophy Type 1 and outlining upcoming clinical milestones.

PepGen Inc. announced a partial clinical hold on its FREEDOM2-DM1 Phase 2 trial by the U.S. FDA, alongside its year-end 2025 financial results and positive Phase 1 data.

PepGen Inc. announced the appointment of Joseph Vittiglio, Esq., as its new Chief Business and Legal Officer, bringing over two decades of executive leadership experience.

PepGen Inc. announced positive third-quarter 2025 financial results and significant clinical progress for its lead DM1 candidate, PGN-EDODM1, extending its cash runway into the second half of 2027.

PepGen Inc. reported a net loss of $17.8 million for Q1 2026, with a significant decrease in R&D expenses and a cash runway extending into the second half of 2027.

PepGen Inc. reported a significant increase in cash and cash equivalents to $142.8 million following a $107.6 million public offering, extending its cash runway into the second half of 2027, despite discontinuing its Duchenne muscular dystrophy program.

PepGen Inc. announced the discontinuation of its Duchenne muscular dystrophy program, PGN-EDO51, due to insufficient dystrophin levels, shifting focus to its Myotonic Dystrophy Type 1 candidate, PGN-EDODM1, amidst substantial doubt about its ability to continue as a going concern.

PepGen Inc. announces its Q1 2025 financial results, highlighting increased R&D spending and providing updates on its PGN-EDO51 and PGN-EDODM1 clinical programs.

PepGen Inc. released its third quarter 2024 financial results, highlighting progress in clinical trials for its lead product candidates and providing updates on its financial position.

PepGen Inc. reports a net loss of $46.4 million for the first six months of 2024, while highlighting progress in clinical trials for its lead product candidates.

PepGen Inc. reports on its 2025 fiscal year, highlighting the advancement of its lead DM1 candidate PGN-EDODM1 into Phase 2 trials, despite an FDA partial clinical hold, and the discontinuation of its DMD program.

PepGen Inc.'s 10-K filing summarizes the company's financial performance for fiscal year 2024 and provides updates on its clinical development programs for Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1).

PepGen Inc. has filed an amendment to its annual report on Form 10-K to include previously omitted internal controls language from its auditor's report.

PepGen Inc.'s 10-K filing details the company's progress in developing oligonucleotide therapies for severe neuromuscular and neurologic diseases, highlighting clinical trial advancements and financial status.

PepGen Inc. Chief Technical Officer Kasra Kasraian sold 1,233 shares of common stock to cover tax withholding obligations upon the vesting of restricted stock units.

PepGen's EVP, Head of R&D, Paul Streck, sold 1,879 shares of common stock to cover tax withholding obligations related to RSU vesting.

PepGen Inc.'s Chief Financial Officer, Noel Donnelly, sold shares to cover mandatory tax withholding obligations related to RSU vesting.

PepGen Inc.'s President and CEO, James G. McArthur, sold 5,275 shares of common stock to cover tax withholding obligations related to RSU vesting.

PepGen's Chief Business & Legal Officer, Joseph Vittiglio, acquired 30,717 restricted stock units and 120,000 stock options.

PepGen Inc.'s Chief Technical Officer, Kasra Kasraian, acquired 34,557 restricted stock units and 135,000 stock options on March 1, 2026.

PepGen Inc. has issued its proxy statement for the 2026 Annual Meeting of Stockholders, scheduled for June 18, 2026, to elect directors and ratify auditors.

PepGen Inc. will hold its annual meeting of stockholders virtually on June 4, 2025, to elect directors and ratify the appointment of KPMG LLP as its independent accounting firm.

PepGen Inc. will hold its 2025 Annual Meeting of Stockholders virtually on June 4, 2025, to elect directors and ratify the appointment of KPMG LLP as its independent accounting firm.

PepGen Inc. will hold its annual meeting of stockholders on June 20, 2024, to vote on the election of directors, an amendment to the certificate of incorporation, ratification of the accounting firm, and adjournment of the meeting if necessary.

PepGen Inc. will host its 2024 Annual Meeting of Stockholders virtually on June 20, 2024, to vote on key proposals including the election of directors, an amendment to limit officer liability, and the ratification of the company's independent auditor.

RA Capital Management and its affiliates increased their beneficial ownership in PepGen Inc. to 29.2% by purchasing 9.375 million shares in a recent public offering.

Viking Global Investors filed an amendment to its Schedule 13G regarding PepGen Inc. to reflect the removal of David C. Ott as a reporting person following his retirement.

Point72 Asset Management, along with Point72 Capital Advisors Inc. and Steven A. Cohen, reported a 3.0% beneficial ownership stake in PepGen Inc., totaling 2,067,432 common shares.

Viking Global Investors and its affiliates have reported a 5.1% beneficial ownership stake in PepGen Inc., totaling 3,482,434 shares of common stock.

Oxford Science Enterprises plc has reported a 7.2% passive ownership stake in PepGen Inc., holding 4,955,388 shares of common stock.

Suvretta Capital Management, Averill Master Fund, and Aaron Cowen jointly report a 0.9% beneficial ownership stake in PepGen Inc. through a Schedule 13G/A filing.

Point72 Asset Management, L.P., along with its affiliates and founder Steven A. Cohen, has disclosed a beneficial ownership of 8.2% in PepGen Inc.'s common stock as of March 31, 2025.